Description
The Pharma and biotech sectors are at a pivotal point in their evolution. The companies are facing significant pressure to change with thinning pipelines, skyrocketing R&D costs, calls for lower prices and a greater regulatory burden, these conditions together with the financial crisis have made the work of creating new drugs harder than ever. Big pharmaceutical companies are being forced to globalize their R&D operations, especially to emerging markets.
Led by China and India, Asia is growing into a drug manufacturing powerhouse and a leading source of drug discovery and high-end innovation during the recent years. Big Pharma companies now rank China as the best location for conducting R&D in Asia, followed by India, Korea and Taiwan, respectively.
